|
|
| Zeile 1: |
Zeile 1: |
| | tempp(5) | | tempp(5) |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=33206792|t=2020. Promising Nanostructured Materials against Enveloped Virus.|pdf=|usr=022}}
| |
| − | {{tp|p=33221521|t=2020. Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism.|pdf=|usr=022}}
| |
| − | {{tp|p=33274176|t=2020. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.|pdf=|usr=022}}
| |
| − | {{tp|p=33283842|t=2020. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33256750|t=2020. COVID-19 vaccine development: What lessons can we learn from TB?|pdf=|usr=022}}
| |
| − | {{tp|p=33284685|t=2020. Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.|pdf=|usr=022}}
| |
| − | {{tp|p=33284679|t=2020. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.|pdf=|usr=022}}
| |
| − | {{tp|p=33287311|t=2020. Geranii Herba as a Potential Inhibitor of SARS-CoV-2 Main 3CL(pro), Spike RBD, and Regulation of Unfolded Protein Response: An In Silico Approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33291560|t=2020. Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications.|pdf=|usr=022}}
| |
| − | {{tp|p=33257051|t=2020. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.|pdf=|usr=022}}
| |
| − | {{tp|p=33224347|t=2020. Tocilizumab in severe COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33281388|t=2019. Strategies and avenues for COVID-19 - Ayurveda perception.|pdf=|usr=022}}
| |
| − | {{tp|p=33276953|t=2020. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.|pdf=|usr=022}}
| |
| − | {{tp|p=33288200|t=2020. The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33276951|t=2020. Dual ELISA using SARS-CoV-2 nucleocapsid protein produced in E. coli and CHO cells reveals epitope masking by N-glycosylation.|pdf=|usr=022}}
| |
| − | {{tp|p=33272566|t=2020. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33292385|t=2020. Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology.|pdf=|usr=022}}
| |
| − | {{tp|p=33254432|t=2020. Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques.|pdf=|usr=022}}
| |
| − | {{tp|p=33194192|t=2020. Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33261847|t=2020. Synthesis, molecular docking, and in silico ADME/Tox profiling studies of new 1-aryl-5-(3-azidopropyl)indol-4-ones: Potential inhibitors of SARS CoV-2 main protease.|pdf=|usr=022}}
| |
| − | {{tp|p=33261845|t=2020. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.|pdf=|usr=022}}
| |
| − | {{tp|p=33261844|t=2020. Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33285430|t=2020. An insight into the interaction between alpha-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.|pdf=|usr=022}}
| |
| − | {{tp|p=33263104|t=2020. Convincing the confidence to conquer COVID-19: From epidemiological intervention to laboratory investigation.|pdf=|usr=022}}
| |
| − | {{tp|p=33257418|t=2020. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective.|pdf=|usr=022}}
| |
| − | {{tp|p=33277291|t=2020. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study.|pdf=|usr=022}}
| |
| − | {{tp|p=33268426|t=2020. Design and rationale of the COVID-19 Critical Care Consortium international, multicentre, observational study.|pdf=|usr=022}}
| |
| − | {{tp|p=33288208|t=2020. Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia.|pdf=|usr=022}}
| |
| − | {{tp|p=33261670|t=2020. Can COVID-19 be a risk for cachexia for patients during intensive care? Narrative review and nutritional recommendations.|pdf=|usr=022}}
| |
| − | {{tp|p=33293741|t=2020. Ensuring equitable access to COVID-19 vaccines.|pdf=|usr=022}}
| |
| − | {{tp|p=33264067|t=2020. Frontrunners in the race to develop a SARS-CoV-2 vaccine.|pdf=|usr=022}}
| |
| − | {{tp|p=33278358|t=2020. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.|pdf=|usr=022}}
| |
| − | {{tp|p=33244174|t=2020. New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=022}}
| |
| − | {{tp|p=33205469|t=2020. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study.|pdf=|usr=022}}
| |
| − | {{tp|p=33262454|t=2020. Structure-based development of human antibody cocktails against SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33262453|t=2020. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models.|pdf=|usr=022}}
| |
| − | {{tp|p=33262452|t=2020. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.|pdf=|usr=022}}
| |
| − | {{tp|p=33262451|t=2020. SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target.|pdf=|usr=022}}
| |
| − | {{tp|p=33278462|t=2020. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.|pdf=|usr=022}}
| |
| − | {{tp|p=33262543|t=2020. COVID-19: Mechanistic model calibration subject to active and varying non-pharmaceutical interventions.|pdf=|usr=022}}
| |
| − | {{tp|p=33292336|t=2020. Anti-COVID-19 drug screening: Frontier concepts and core technologies.|pdf=|usr=022}}
| |
| − | {{tp|p=33275095|t=2020. Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia.|pdf=|usr=022}}
| |
| − | {{tp|p=33275094|t=2020. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33292313|t=2020. Vitamin D and Covid-19: an update on evidence and potential therapeutic implications.|pdf=|usr=022}}
| |
| − | {{tp|p=33292691|t=2020. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies.|pdf=|usr=022}}
| |
| − | {{tp|p=33257340|t=2020. Difficultes associees a l'evaluation des vaccins contre le SRAS-CoV-2 pendant la pandemie de COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33229355|t=2020. Efficacite et innocuite des corticosteroides dans le traitement de la COVID-19 selon des donnees pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitaliere et le syndrome de detresse respiratoire aigue : revue systematique et meta-analyse.|pdf=|usr=022}}
| |
| − | {{tp|p=33260103|t=2020. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33260034|t=2020. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.|pdf=|usr=022}}
| |
| − | {{tp|p=33276271|t=2020. Techniques assisting peptide vaccine and peptidomimetic design. Sidechain exposure in the SARS-CoV-2 spike glycoprotein.|pdf=|usr=022}}
| |
| − | {{tp|p=33217661|t=2020. Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs.|pdf=|usr=022}}
| |
| − | {{tp|p=33283069|t=2020. Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa).|pdf=|usr=022}}
| |
| − | {{tp|p=33296558|t=2020. A Mechanism-based Pharmacokinetic Model of Remdesivir Leveraging Interspecies Scaling to Simulate COVID-19 Treatment in Humans.|pdf=|usr=022}}
| |
| − | {{tp|p=33183348|t=2020. Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study.|pdf=|usr=022}}
| |
| − | {{tp|p=33287853|t=2020. The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study.|pdf=|usr=022}}
| |
| − | {{tp|p=33269148|t=2020. Does Nicotine Prevent Cytokine Storms in COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33293238|t=2020. SARS-CoV-2: Targeted managements and vaccine development.|pdf=|usr=022}}
| |
| − | {{tp|p=33275276|t=2020. Editorial - Role of Highly Active Antiretroviral Therapy (HAART) for the COVID-19 treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33275275|t=2020. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33275267|t=2020. The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.|pdf=|usr=022}}
| |
| − | {{tp|p=33289021|t=2020. A survey of US hospitals' criteria for the allocation of remdesivir to treat COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33293273|t=2020. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.|pdf=|usr=022}}
| |
| − | {{tp|p=33267767|t=2020. Covid-19: Urgent call to action.|pdf=|usr=022}}
| |
| − | {{tp|p=33288636|t=2020. Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33293006|t=2020. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33258925|t=2020. A pocket guide on how to structure SARS-CoV-2 drugs and therapies.|pdf=|usr=022}}
| |
| − | {{tp|p=33292872|t=2020. The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia.|pdf=|usr=022}}
| |
| − | {{tp|p=33264786|t=2020. Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.|pdf=|usr=022}}
| |
| − | {{tp|p=33257346|t=2020. Vaccinating the UK against covid-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33268462|t=2020. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy.|pdf=|usr=022}}
| |
| − | {{tp|p=33268330|t=2020. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week.|pdf=|usr=022}}
| |
| − | {{tp|p=33245577|t=2020. Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review.|pdf=|usr=022}}
| |
| − | {{tp|p=33226664|t=2020. Pharmacokinetics under the COVID-19 Storm.|pdf=|usr=022}}
| |
| − | {{tp|p=33217038|t=2020. Chasing COVID-19 chemotherapeutics without putting the cart before the horse.|pdf=|usr=022}}
| |
| − | {{tp|p=33269470|t=2020. Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: a physiologically-based pharmacokinetic/pharmacodynamic analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33289156|t=2020. Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future.|pdf=|usr=022}}
| |
| − | {{tp|p=33275511|t=2020. Status of vaccine development for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33275510|t=2020. A COVID-19 vaccine-dare to dream.|pdf=|usr=022}}
| |
| − | {{tp|p=33283265|t=2020. Low bioavailability hinders drug discovery against COVID-19, guided by in silico docking.|pdf=|usr=022}}
| |
| − | {{tp|p=33252988|t=2021. Low-dose X-ray therapy for COVID-19: lessons from the past.|pdf=|usr=022}}
| |
| − | {{tp|p=33285567|t=2020. Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33279954|t=2020. A review of COVID-19 biomarkers and drug targets: resources and tools.|pdf=|usr=022}}
| |
| − | {{tp|p=33253353|t=2020. Drug repurposing for COVID-19: could vitamin C combined with glycyrrhizic acid be at play by the findings of Li et al.'s database-based network pharmacology analysis?|pdf=|usr=022}}
| |
| − | {{tp|p=33183365|t=2020. Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.|pdf=|usr=022}}
| |
| − | {{tp|p=33211371|t=2020. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.|pdf=|usr=022}}
| |
| − | {{tp|p=33289334|t=2020. Repurposing potential of FDA approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.|pdf=|usr=022}}
| |
| − | {{tp|p=33283984|t=2020. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.|pdf=|usr=022}}
| |
| − | {{tp|p=33285564|t=2020. Paradoxes and uncertainties of immunomodulatory treatments in the fight against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33270137|t=2020. Dose-response effects of hydroxychloroquine on prophylaxis against SARS-CoV-2 / COVID-19 infection.|pdf=|usr=022}}
| |
| − | {{tp|p=33231098|t=2020. Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33279656|t=2020. Reporting and design of randomized controlled trials for COVID-19: A systematic review.|pdf=|usr=022}}
| |
| − | {{tp|p=33292107|t=2020. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.|pdf=|usr=022}}
| |
| − | {{tp|p=33267759|t=2020. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.|pdf=|usr=022}}
| |
| − | {{tp|p=33272178|t=2020. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.|pdf=|usr=022}}
| |
| − | {{tp|p=33272180|t=2020. Circadian Clock Genes: Targeting Innate Immunity for Antiviral Strategies Against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33284199|t=2020. COVID-19 in older persons: the role of nutrition.|pdf=|usr=022}}
| |
| − | {{tp|p=33278121|t=2020. Emerging cellular and pharmacologic therapies for acute respiratory distress syndrome.|pdf=|usr=022}}
| |
| − | {{tp|p=33278108|t=2020. COVID-19 vaccine development: a pediatric perspective.|pdf=|usr=022}}
| |
| − | {{tp|p=33292123|t=2020. Molecular descriptors of some chemicals that prevent COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33261538|t=2020. Touting Traditional Knowledge and Herbal Medicine to Combat and Prevent COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33238863|t=2020. Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the SARS-CoV-2 Cytokine Storm.|pdf=|usr=022}}
| |
| − | {{tp|p=33213322|t=2020. Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33213320|t=2020. The impact of traditional plants and their secondary metabolites in the discovery of COVID-19 treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33200697|t=2020. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33267756|t=2020. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A new Route to Fight against COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33238848|t=2020. Mesenchymal stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines.|pdf=|usr=022}}
| |
| − | {{tp|p=33183205|t=2020. Recent Advances in Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.|pdf=|usr=022}}
| |
| − | {{tp|p=33292135|t=2020. Docking paradigm: Drug Design.|pdf=|usr=022}}
| |
| − | {{tp|p=33292134|t=2020. An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors.|pdf=|usr=022}}
| |
| − | {{tp|p=33262119|t=2020. Covid-19 vaccination-we need more than the 'mum test'.|pdf=|usr=022}}
| |
| − | {{tp|p=33290205|t=2020. Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.|pdf=|usr=022}}
| |
| − | {{tp|p=33270024|t=2020. Therapeutic targeting of interleukin-6 for the treatment of COVID-19.|pdf=|usr=022}}
| |
| − |
| |
| − | {{tp|p=33257213|t=2020. Stem cell therapy in coronavirus disease 2019: current evidence and future potential.|pdf=|usr=022}}
| |
| − | {{tp|p=33251300|t=2020. Dataset of potential Rhizoma Polygonati compound-druggable targets and partial pharmacokinetics for treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33249199|t=2020. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.|pdf=|usr=022}}
| |
| − | {{tp|p=33279832|t=2020. Letter in response to the article: Pros and cons for use of statins in 59 people with coronavirus disease-19 (COVID-19)(Ray, S et al.).|pdf=|usr=022}}
| |
| − | {{tp|p=33256258|t=2020. Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?|pdf=|usr=022}}
| |
| − | {{tp|p=33239864|t=2020. Repurposing Anti-Cancer Drugs for COVID-19 Treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33245507|t=2020. Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33259037|t=2020. Dosing Considerations for Antibodies Against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33232870|t=2020. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.|pdf=|usr=022}}
| |
| − | {{tp|p=33279857|t=2020. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.|pdf=|usr=022}}
| |
| − | {{tp|p=33283178|t=2020. The "sex gap" in COVID-19 trials: a scoping review.|pdf=|usr=022}}
| |
| − | {{tp|p=33251500|t=2020. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33232205|t=2020. Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate.|pdf=|usr=022}}
| |
| − | {{tp|p=33241728|t=2020. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.|pdf=|usr=022}}
| |
| − | {{tp|p=33235976|t=2020. Combating COVID-19 with tissue engineering: a review.|pdf=|usr=022}}
| |
| − | {{tp|p=33225219|t=2020. Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles.|pdf=|usr=022}}
| |
| − | {{tp|p=33219496|t=2020. The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed.|pdf=|usr=022}}
| |
| − | {{tp|p=33205620|t=2020. Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension.|pdf=|usr=022}}
| |
| − | {{tp|p=33205539|t=2020. Hypothetical dysfunction of the epithelial sodium channel may justify neurohumoral blockade in coronavirus disease 2019.|pdf=|usr=022}}
| |
| − | {{tp|p=33244631|t=2020. Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".|pdf=|usr=022}}
| |
| − | {{tp|p=33241457|t=2020. Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts.|pdf=|usr=022}}
| |
| − | {{tp|p=33239282|t=2020. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.|pdf=|usr=022}}
| |
| − | {{tp|p=33214132|t=2020. Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy.|pdf=|usr=022}}
| |
| − | {{tp|p=33204368|t=2020. Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): a scoping review.|pdf=|usr=022}}
| |
| − | {{tp|p=33200007|t=2020. The role of physical activity on mental health and quality of life during COVID-19 outbreak: A cross-sectional study.|pdf=|usr=022}}
| |
| − | {{tp|p=33225401|t=2020. Prognostic implications of vitamin D in patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33225400|t=2020. Reply to: Prognostic implications of vitamin D in patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33200304|t=2020. Compassionate use of remdesivir in children with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33249077|t=2020. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2).|pdf=|usr=022}}
| |
| − | {{tp|p=33245898|t=2020. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.|pdf=|usr=022}}
| |
| − | {{tp|p=33227287|t=2020. A comprehensive review on potential therapeutics interventions for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33227285|t=2020. A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33275961|t=2020. Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33271151|t=2020. Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33214204|t=2020. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia.|pdf=|usr=022}}
| |
| − | {{tp|p=33224256|t=2020. Investigation of the Potential Mechanism Governing the Effect of the Shen Zhu San on COVID-19 by Network Pharmacology.|pdf=|usr=022}}
| |
| − | {{tp|p=33204291|t=2020. Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33235797|t=2020. Old friends meet a new foe: A potential role for immune-priming parasites in mitigating COVID-19 morbidity and mortality.|pdf=|usr=022}}
| |
| − | {{tp|p=33262810|t=2021. Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).|pdf=|usr=022}}
| |
| − | {{tp|p=33199997|t=2020. Lactoferrin for the treatment of COVID-19 (Review).|pdf=|usr=022}}
| |
| − | {{tp|p=33204411|t=2020. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33233560|t=2020. Food Ingredients and Active Compounds against the Coronavirus Disease (COVID-19) Pandemic: A Comprehensive Review.|pdf=|usr=022}}
| |
| − | {{tp|p=33224928|t=2020. Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33251185|t=2020. Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico Methods and Benchmarking.|pdf=|usr=022}}
| |
| − | {{tp|p=33240216|t=2020. A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic.|pdf=|usr=022}}
| |
| − | {{tp|p=33281876|t=2020. Identification of Potential Key Agents for Targeting RNA-Dependent RNA Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug Screening.|pdf=|usr=022}}
| |
| − | {{tp|p=33281589|t=2020. Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms.|pdf=|usr=022}}
| |
| − | {{tp|p=33250897|t=2020. Rapid Response Subunit Vaccine Design in the Absence of Structural Information.|pdf=|usr=022}}
| |
| − | {{tp|p=33240278|t=2020. Adjuvants for Coronavirus Vaccines.|pdf=|usr=022}}
| |
| − | {{tp|p=33240265|t=2020. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.|pdf=|usr=022}}
| |
| − | {{tp|p=33262750|t=2020. Can Algal Derived Bioactive Metabolites Serve as Potential Therapeutics for the Treatment of SARS-CoV-2 Like Viral Infection?|pdf=|usr=022}}
| |
| − | {{tp|p=33262747|t=2020. Current and Future Direct-Acting Antivirals Against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33282914|t=2020. Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.|pdf=|usr=022}}
| |
| − | {{tp|p=33240915|t=2020. Fasting Ramadan During COVID-19 Pandemic: Immunomodulatory Effect.|pdf=|usr=022}}
| |
| − | {{tp|p=33240092|t=2020. Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019.|pdf=|usr=022}}
| |
| − | {{tp|p=33240091|t=2020. Challenges for Drug Repurposing in the COVID-19 Pandemic Era.|pdf=|usr=022}}
| |
| − | {{tp|p=33250777|t=2020. A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33224923|t=2020. Is It Important to Perform Physical Activity During Coronavirus Pandemic (COVID-19)? Driving Action for a Correct Exercise Plan.|pdf=|usr=022}}
| |
| − | {{tp|p=33240967|t=2020. Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro.|pdf=|usr=022}}
| |
| − | {{tp|p=33215042|t=2020. Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33269342|t=2020. Withania somnifera as a potential future drug molecule for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33225723|t=2020. The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design.|pdf=|usr=022}}
| |
| − | {{tp|p=33215525|t=2020. The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic.|pdf=|usr=022}}
| |
| − | {{tp|p=33206554|t=2020. Chloroquine/hydroxycloroquine and COVID-19: need to know more about.|pdf=|usr=022}}
| |
| − | {{tp|p=33244389|t=2020. Possible role of zinc (Zn) as an adjunctive therapy in gastrointestinal symptoms of COVID-19 infectious disease.|pdf=|usr=022}}
| |
| − | {{tp|p=33294721|t=2020. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease.|pdf=|usr=022}}
| |
| − | {{tp|p=33292350|t=2020. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33296685|t=2020. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.|pdf=|usr=022}}
| |
| − | {{tp|p=33294307|t=2021. Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study.|pdf=|usr=022}}
| |
| − | {{tp|p=33280066|t=2020. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.|pdf=|usr=022}}
| |
| − | {{tp|p=33293837|t=2020. Targeting Polyamine Metabolism for Control of Human Viral Diseases.|pdf=|usr=022}}
| |
| − | {{tp|p=33290969|t=2020. A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33285283|t=2020. COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.|pdf=|usr=022}}
| |
| − | {{tp|p=33291769|t=2020. Interrelated Mechanism by Which the Methide Quinone Celastrol, Obtained from the Roots of Tripterygium wilfordii, Inhibits Main Protease 3CL(pro) of COVID-19 and Acts as Superoxide Radical Scavenger.|pdf=|usr=022}}
| |
| − | {{tp|p=33292521|t=2020. A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: case studies for rare diseases and COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33292930|t=2020. Ensuring Safety of Operation Warp Speed Vaccines for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33256484|t=2020. Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis.|pdf=|usr=022}}
| |
| − | {{tp|p=33283567|t=2020. Repurposing drugs for the management of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33270490|t=2020. Recent progress in the repurposing of drugs/molecules for the management of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33280467|t=2020. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.|pdf=|usr=022}}
| |
| − | {{tp|p=33270594|t=2020. BIOCHEMICAL ASPECTS OF SYMPTOMATIC TREATMENT IN PATIENTS WITH COVID-19 (REVIEW).|pdf=|usr=022}}
| |
| − | {{tp|p=33295829|t=2020. Exploring the possible use of saponin adjuvants in COVID-19 vaccine.|pdf=|usr=022}}
| |
| − | {{tp|p=33270497|t=2020. COVID-19 in the elderly people and advances in vaccination approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33270484|t=2020. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects.|pdf=|usr=022}}
| |
| − | {{tp|p=33270478|t=2020. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.|pdf=|usr=022}}
| |
| − | {{tp|p=33270474|t=2020. Vaccine safety - is the SARS-CoV-2 vaccine any different?|pdf=|usr=022}}
| |
| − | {{tp|p=33281124|t=2020. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33283773|t=2020. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33257603|t=2020. Successful Convalescent Plasma Therapy in a Child With Severe Coronavirus Disease.|pdf=|usr=022}}
| |
| − | {{tp|p=33283692|t=2020. IODINE MOUTHWASHES AS DETERRENTS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2).|pdf=|usr=022}}
| |
| − | {{tp|p=33292147|t=2020. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.|pdf=|usr=022}}
| |
| − | {{tp|p=33290767|t=2020. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33191905|t=2020. A case report of hydroxychloroquine-induced auditory and visual hallucination.|pdf=|usr=022}}
| |
| − | {{tp|p=33280207|t=2020. Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33260201|t=2020. Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials.|pdf=|usr=022}}
| |
| − | {{tp|p=33247641|t=2020. Effectiveness of Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID 19 Patients: A Systematic Review and Meta-Analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33292085|t=2020. Depicting the inhibitory potential of polyphenols from Isatis indigotica root against the main protease of SARS CoV-2 using computational approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33292056|t=2020. Sensing the interactions between carbohydrate-binding agents and N-linked glycans of SARS-CoV-2 spike glycoprotein using molecular docking and simulation studies.|pdf=|usr=022}}
| |
| − | {{tp|p=33289456|t=2020. Virtual screening of phytoconstituents from miracle herb nigella sativa targeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33259429|t=2020. Antimicrobial Resistance, the COVID-19 Pandemic, and Lessons for the Orthopaedic Community.|pdf=|usr=022}}
| |
| − | {{tp|p=33274473|t=2020. Science and Evidence-based Review and Approval of COVID-19 Vaccines: A Statement of Support for the U.S. FDA.|pdf=|usr=022}}
| |
| − | {{tp|p=33264251|t=2020. Use of Corticosteroids in COVID-19: Should It Be Considered as a Standard-of-Care Therapy?|pdf=|usr=022}}
| |
| − | {{tp|p=33291204|t=2020. Prognostic Utility of Baseline 25-Hydroxy Vitamin D Levels in Hospitalised COVID-19 Patients: Hope or Hype?|pdf=|usr=022}}
| |
| − | {{tp|p=33291202|t=2020. Vitamin D in COVID-19 Pneumonia: High Yield with Low Risk.|pdf=|usr=022}}
| |
| − | {{tp|p=33291194|t=2020. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33275483|t=2020. A Study of Potential SARS-CoV-2 Antiviral Drugs and Preliminary Research of Their Molecular Mechanism, Based on Anti-SARS-CoV Drug Screening and Molecular Dynamics Simulation.|pdf=|usr=022}}
| |
| − | {{tp|p=33276017|t=2020. Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33274479|t=2020. Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.|pdf=|usr=022}}
| |
| − | {{tp|p=33275101|t=2020. Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2: a case description.|pdf=|usr=022}}
| |
| − | {{tp|p=33289151|t=2020. Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China.|pdf=|usr=022}}
| |
| − | {{tp|p=33270225|t=2020. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.|pdf=|usr=022}}
| |
| − | {{tp|p=33289122|t=2020. Hidden in plain sight: The effects of BCG vaccination in COVID-19 pandemic.|pdf=|usr=022}}
| |
| − |
| |
| − | {{tp|p=33244378|t=2020. Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33244375|t=2020. Nutrition, the digestive system and immunity in COVID-19 infection.|pdf=|usr=022}}
| |
| − | {{tp|p=33275129|t=2020. Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33256385|t=2020. Complement C5 inhibition in patients with COVID-19 - a promising target?|pdf=|usr=022}}
| |
| − | {{tp|p=33256382|t=2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.|pdf=|usr=022}}
| |
| − | {{tp|p=33207372|t=2020. The Role of Glucocorticoids in the Management of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33185497|t=2020. Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33230502|t=2020. Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.|pdf=|usr=022}}
| |
| − | {{tp|p=33244901|t=2020. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.|pdf=|usr=022}}
| |
| − | {{tp|p=33275896|t=2020. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.|pdf=|usr=022}}
| |
| − | {{tp|p=33235833|t=2020. Colchicine in Dermatology: Rediscovering an Old Drug with Novel Uses.|pdf=|usr=022}}
| |
| − | {{tp|p=33263242|t=2020. Repositioning vitamin C as a promising option to alleviate complications associated with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33264668|t=2020. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.|pdf=|usr=022}}
| |
| − | {{tp|p=33257619|t=2020. The shortcomings of tocilizumab in COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33196946|t=2020. COVID-19 and nutriceutical therapies, especially using zinc to supplement antimicrobials.|pdf=|usr=022}}
| |
| − | {{tp|p=33263073|t=2020. DECODING INFORMATION ON COVID - 19: ONTOLOGICAL APPROACH TOWARDS DESIGN POSSIBLE THERAPEUTICS.|pdf=|usr=022}}
| |
| − | {{tp|p=33251326|t=2020. Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019.|pdf=|usr=022}}
| |
| − | {{tp|p=33200089|t=2020. A multiple peptides vaccine against COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the immunoinformatics approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33200088|t=2020. Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33208294|t=2020. The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study.|pdf=|usr=022}}
| |
| − | {{tp|p=33221168|t=2020. Potential role of interferons in treating COVID-19 patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33278747|t=2020. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.|pdf=|usr=022}}
| |
| − | {{tp|p=33214093|t=2020. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.|pdf=|usr=022}}
| |
| − | {{tp|p=33259917|t=2020. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.|pdf=|usr=022}}
| |
| − | {{tp|p=33259916|t=2020. Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33259913|t=2020. A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.|pdf=|usr=022}}
| |
| − | {{tp|p=33213829|t=2020. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33257908|t=2020. Vitamin D and COVID-19: Does a Deficiency Point Towards an Unfavorable Outcome?|pdf=|usr=022}}
| |
| − | {{tp|p=33212762|t=2020. Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy?|pdf=|usr=022}}
| |
| − | {{tp|p=33248244|t=2020. Novaferon, Treatment in COVID-19 Patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33248243|t=2020. Reply to "Novaferon, Treatment in COVID-19 Patients".|pdf=|usr=022}}
| |
| − | {{tp|p=33278625|t=2020. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.|pdf=|usr=022}}
| |
| − | {{tp|p=33262589|t=2020. Silver-Based Nanomaterials as Therapeutic Agents Against Coronaviruses: A Review.|pdf=|usr=022}}
| |
| − | {{tp|p=33278503|t=2020. Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Final Results of a Pilot Study.|pdf=|usr=022}}
| |
| − | {{tp|p=33219912|t=2020. Vitamin D and SARS-CoV-2 infection-evolution of evidence supporting clinical practice and policy development : A position statement from the Covit-D Consortium.|pdf=|usr=022}}
| |
| − | {{tp|p=33206336|t=2020. Remdesivir versus ritonavir/lopinavir in COVID-19 patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33283177|t=2020. Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase.|pdf=|usr=022}}
| |
| − | {{tp|p=33205008|t=2020. Innate and Adaptive Immunity of Murine Neural Stem Cell-Derived piRNA Exosomes/Microvesicles against Pseudotyped SARS-CoV-2 and HIV-Based Lentivirus.|pdf=|usr=022}}
| |
| − | {{tp|p=33249784|t=2020. Treating Epilepsy Patients with Investigational Anti-COVID-19 Drugs: Recommendations by the Israeli Chapter of the ILAE.|pdf=|usr=022}}
| |
| − | {{tp|p=33236590|t=2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.|pdf=|usr=022}}
| |
| − | {{tp|p=33236585|t=2020. Bacillus Calmette-Guerin (BCG) as a Protective Factor for COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33236583|t=2020. Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe.|pdf=|usr=022}}
| |
| − | {{tp|p=33220354|t=2020. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.|pdf=|usr=022}}
| |
| − | {{tp|p=33232684|t=2020. Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2.|pdf=|usr=022}}
| |
| − | {{tp|p=33262017|t=2020. Understanding COVID - 19 pandemic - A comprehensive Ayurvedic perspective.|pdf=|usr=022}}
| |
| − | {{tp|p=33262559|t=2020. A Critical Analysis of CTRI registered AYUSH studies for COVID- 19.|pdf=|usr=022}}
| |
| − | {{tp|p=33250601|t=2020. Network pharmacology of AYUSH recommended immune-boosting medicinal plants against COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33210561|t=2020. Structure-based identification of potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=022}}
| |
| − | {{tp|p=33200683|t=2020. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33200681|t=2020. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m(pro)): a molecular docking, molecular dynamics and structure-activity relationship studies.|pdf=|usr=022}}
| |
| − | {{tp|p=33200678|t=2020. Computational investigation for identification of potential phytochemicals and antiviral drugs as potential inhibitors for RNA-dependent RNA polymerase of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33200673|t=2020. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33183178|t=2020. Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches.|pdf=|usr=022}}
| |
| − | {{tp|p=33241658|t=2020. Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin.|pdf=|usr=022}}
| |
| − | {{tp|p=33211389|t=2020. Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33250934|t=2020. A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: case studies for rare diseases and COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33211672|t=2020. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers.|pdf=|usr=022}}
| |
| − | {{tp|p=33270604|t=2020. Generating evidence for therapeutic effects: the need for well-conducted randomized trials.|pdf=|usr=022}}
| |
| − | {{tp|p=33256141|t=2020. Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial.|pdf=|usr=022}}
| |
| − | {{tp|p=33238464|t=2020. Drug Repurposing Approaches to Combating Viral Infections.|pdf=|usr=022}}
| |
| − | {{tp|p=33213035|t=2020. Why Methodology Is Important: Coffee as a Candidate Treatment for COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33245242|t=2020. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.|pdf=|usr=022}}
| |
| − | {{tp|p=33260010|t=2020. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.|pdf=|usr=022}}
| |
| − | {{tp|p=33280995|t=2020. Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS.|pdf=|usr=022}}
| |
| − | {{tp|p=33264025|t=2020. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.|pdf=|usr=022}}
| |
| − | {{tp|p=33294881|t=2020. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33263084|t=2020. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.|pdf=|usr=022}}
| |
| − | {{tp|p=33288313|t=2020. Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols?|pdf=|usr=022}}
| |
| − | {{tp|p=33277107|t=2020. Passive inhaled mRNA vaccination for SARS-Cov-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33257090|t=2020. COVID-19's toll on the elderly and those with diabetes mellitus - Is vitamin B12 deficiency an accomplice?|pdf=|usr=022}}
| |
| − | {{tp|p=33295312|t=2020. SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar Garcia-Rivera PhD.|pdf=|usr=022}}
| |
| − | {{tp|p=33294198|t=2020. Evaluation of electrolyte status of sodium, potassium and magnesium, and fasting blood sugar at the initial admission of individuals with COVID-19 without underlying disease in Golestan Hospital, Kermanshah.|pdf=|usr=022}}
| |
| − | {{tp|p=33291720|t=2020. The Benefits of Vitamin D Supplementation for Athletes: Better Performance and Reduced Risk of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33290972|t=2020. In silico screening of potential anti-COVID-19 bioactive natural constituents from food sources by molecular docking.|pdf=|usr=022}}
| |
| − | {{tp|p=33288411|t=2020. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy.|pdf=|usr=022}}
| |
| − | {{tp|p=33274249|t=2020. COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.|pdf=|usr=022}}
| |
| − | {{tp|p=33291642|t=2020. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=022}}
| |
| − |
| |
| − | {{tp|p=33262924|t=2021. Probiotics in the prophylaxis of COVID-19: something is better than nothing.|pdf=|usr=022}}
| |
| − | {{tp|p=33267577|t=2020. Highly Effective Inactivation of SARS-CoV-2 by Conjugated Polymers and Oligomers.|pdf=|usr=022}}
| |
| − | {{tp|p=33283100|t=2020. Similarity and Specificity of Traditional Chinese Medicine Formulas for Management of Coronavirus Disease 2019 and Rheumatoid Arthritis.|pdf=|usr=022}}
| |
| − | {{tp|p=33201345|t=2020. Use of DPP-4 inhibitors in patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33201344|t=2020. Reply to letter to the editor regarding "Use of DPP-4 inhibitors in patients with COVID-19".|pdf=|usr=022}}
| |
| − | {{tp|p=33224722|t=2020. Neutralizing antibodies for the treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33189768|t=2020. Peptide and peptide-based inhibitors of SARS-CoV-2 entry.|pdf=|usr=022}}
| |
| − | {{tp|p=33269093|t=2020. A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33236114|t=2020. Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality.|pdf=|usr=022}}
| |
| − | {{tp|p=33262663|t=2020. Antiviral Effects of Oleandrin.|pdf=|usr=022}}
| |
| − | {{tp|p=33274246|t=2020. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33268271|t=2020. A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.|pdf=|usr=022}}
| |
| − | {{tp|p=33284675|t=2020. Home-based exercise is associated with improved cardiac functional performance in patients after acute myocardial infarction.|pdf=|usr=022}}
| |
| − | {{tp|p=33278866|t=2020. Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia.|pdf=|usr=022}}
| |
| − | {{tp|p=33275385|t=2020. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?|pdf=|usr=022}}
| |
| − | {{tp|p=33282414|t=2020. Is there a place for anti-inflammatory therapy in COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33256746|t=2020. Logistics of an advanced therapy medicinal product during COVID-19 pandemic in Italy: successful delivery of mesenchymal stromal cells in dry ice.|pdf=|usr=022}}
| |
| − | {{tp|p=33276849|t=2020. In Reply - Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33276848|t=2020. Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33254589|t=2020. Role of testosterone in COVID-19 patients - A double-edged sword?|pdf=|usr=022}}
| |
| − | {{tp|p=33254584|t=2020. A hypothesis for examining dihydroxyacetone, the active component in sunless tanning products, as a topical prophylactic against SARS-COV-2 transmission.|pdf=|usr=022}}
| |
| − | {{tp|p=33254581|t=2020. Phosphatidylglycerol and surfactant: A potential treatment for COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33254580|t=2020. Periodontal disease and targeted prevention using aMMP-8 point-of-care oral fluid analytics in the COVID-19 era.|pdf=|usr=022}}
| |
| − | {{tp|p=33254579|t=2020. Host - virus - drug interactions as determinants of COVID-19's phenotypes: A data-driven hypothesis.|pdf=|usr=022}}
| |
| − | {{tp|p=33254564|t=2020. Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia?|pdf=|usr=022}}
| |
| − | {{tp|p=33254561|t=2020. Potential of electric stimulation for the management of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33254555|t=2020. COVID-19: Endogenous Retinoic Acid Theory and Retinoic Acid Depletion Syndrome.|pdf=|usr=022}}
| |
| − | {{tp|p=33254551|t=2020. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33254548|t=2020. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.|pdf=|usr=022}}
| |
| − | {{tp|p=33254534|t=2020. Red blood cell exchange for SARS-CoV-2: A Gemini of therapeutic opportunities.|pdf=|usr=022}}
| |
| − | {{tp|p=33254531|t=2020. Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33254515|t=2020. Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus?|pdf=|usr=022}}
| |
| − | {{tp|p=33254514|t=2020. Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33254510|t=2020. Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33254506|t=2020. A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression.|pdf=|usr=022}}
| |
| − | {{tp|p=33254502|t=2020. The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33254498|t=2020. Can charcoal improve outcomes in COVID-19 infections?|pdf=|usr=022}}
| |
| − | {{tp|p=33254486|t=2020. Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV.|pdf=|usr=022}}
| |
| − | {{tp|p=33254484|t=2020. Methylene blue may have a role in the treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33264276|t=2020. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.|pdf=|usr=022}}
| |
| − | {{tp|p=33285740|t=2020. Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia: A case report.|pdf=|usr=022}}
| |
| − | {{tp|p=33285727|t=2020. The efficacy and safety of Xuebijing injection for corona virus disease 2019: A protocol for a systematic review and meta-analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33265927|t=2020. SARS-CoV-2 Inhibition by Sulfonated Compounds.|pdf=|usr=022}}
| |
| − | {{tp|p=33256227|t=2020. Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro.|pdf=|usr=022}}
| |
| − | {{tp|p=33260370|t=2020. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study.|pdf=|usr=022}}
| |
| − | {{tp|p=33260592|t=2020. Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein.|pdf=|usr=022}}
| |
| − | {{tp|p=33255849|t=2020. In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33255326|t=2020. Novel Small-Molecule Scaffolds as Candidates against the SARS Coronavirus 2 Main Protease: A Fragment-Guided in Silico Approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33255253|t=2020. Alkaloids: Therapeutic Potential against Human Coronaviruses.|pdf=|usr=022}}
| |
| − | {{tp|p=33287144|t=2020. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge.|pdf=|usr=022}}
| |
| − | {{tp|p=33271751|t=2020. Identification of Persuasive Antiviral Natural Compounds for COVID-19 by Targeting Endoribonuclease NSP15: A Structural-Bioinformatics Approach.|pdf=|usr=022}}
| |
| − | {{tp|p=33269948|t=2020. New proposal involving nanoformulated melatonin targeted to the mitochondria as a potential COVID-19 treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33257686|t=2020. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.|pdf=|usr=022}}
| |
| − | {{tp|p=33261189|t=2020. Reply to: "Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: Vitamin D Deficiency and Outcome of COVID-19 Patients. Nutrients 2020, 12, 2757".|pdf=|usr=022}}
| |
| − | {{tp|p=33260798|t=2020. Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: "Vitamin D Deficiency and Outcome of COVID-19 Patients". Nutrients 2020, 12, 2757.|pdf=|usr=022}}
| |
| − | {{tp|p=33277150|t=2020. Potential roles of micronutrient deficiency and immune system dysfunction in the coronavirus disease 2019 (COVID-19) pandemic.|pdf=|usr=022}}
| |
| − | {{tp|p=33277149|t=2020. Nutritional therapy for patients with coronavirus disease 2019 (COVID-19): Practical protocol from a single center highly affected by an outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.|pdf=|usr=022}}
| |
| − | {{tp|p=33257110|t=2020. Re. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): rationale and feasibility of a shared pragmatic protocol.|pdf=|usr=022}}
| |
| − | {{tp|p=33282067|t=2020. Electrocardiogrammes d un patient COVID-19 traite par l association hydroxychloroquine et azithromycine.|pdf=|usr=022}}
| |
| − | {{tp|p=33282063|t=2020. 'Any and every cure for COVID-19': an imminent epidemic of alternative remedies amidst the pandemic?|pdf=|usr=022}}
| |
| − | {{tp|p=33261173|t=2020. Emetine Is Not Ipecac: Considerations for Its Use as Treatment for SARS-CoV2.|pdf=|usr=022}}
| |
| − | {{tp|p=33260813|t=2020. Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics.|pdf=|usr=022}}
| |
| − | {{tp|p=33290397|t=2020. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.|pdf=|usr=022}}
| |
| − | {{tp|p=33264337|t=2020. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).|pdf=|usr=022}}
| |
| − | {{tp|p=33282201|t=2020. Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33282314|t=2021. Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.|pdf=|usr=022}}
| |
| − | {{tp|p=33262668|t=2020. Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.|pdf=|usr=022}}
| |
| − | {{tp|p=33281478|t=2020. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.|pdf=|usr=022}}
| |
| − | {{tp|p=33257760|t=2020. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).|pdf=|usr=022}}
| |
| − | {{tp|p=33257716|t=2020. Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2.|pdf=|usr=022}}
| |
| − | {{tp|p=33277573|t=2020. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33262433|t=2020. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.|pdf=|usr=022}}
| |
| − | {{tp|p=33262415|t=2020. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33262359|t=2020. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir.|pdf=|usr=022}}
| |
| − | {{tp|p=33262067|t=2020. The immunology of SARS-CoV-2 infections and vaccines.|pdf=|usr=022}}
| |
| − | {{tp|p=33262793|t=2020. Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33277207|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33285298|t=2020. Emergence of Ancient Convalescent plasma (CP) Therapy: to Manage COVID-19 Pandemic.|pdf=|usr=022}}
| |
| − | {{tp|p=33281063|t=2020. Combining Antivirals and Immunomodulators to Fight COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33260553|t=2020. Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=022}}
| |
| − | {{tp|p=33279318|t=2020. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.|pdf=|usr=022}}
| |
| − | {{tp|p=33291245|t=2020. Efforts at COVID-19 Vaccine Development: Challenges and Successes.|pdf=|usr=022}}
| |
| − | {{tp|p=33291455|t=2020. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.|pdf=|usr=022}}
| |
| − | {{tp|p=33296027|t=2020. Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33269265|t=2020. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports.|pdf=|usr=022}}
| |
| − | {{tp|p=33269910|t=2020. Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19?|pdf=|usr=022}}
| |
| − | {{tp|p=33214807|t=2020. Targeted Disassembling of SARS-CoV-2 as It Gets Ready for Cell Penetration.|pdf=|usr=022}}
| |
| − | {{tp|p=33296498|t=2020. Effects of Inhaled Nitric Oxide in COVID-19 induced ARDS - is it worthwhile?|pdf=|usr=022}}
| |
| − | {{tp|p=33273140|t=2020. First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study.|pdf=|usr=022}}
| |
| − | {{tp|p=33202150|t=2020. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.|pdf=|usr=022}}
| |
| − | {{tp|p=33279332|t=2020. The role of mesenchymal stem/stromal cells in the acute clinical setting.|pdf=|usr=022}}
| |
| − | {{tp|p=33295569|t=2020. Inteligencia artificial como apoyo a intervenciones no farmacologicas para combatir la COVID-19.|pdf=|usr=022}}
| |
| − | {{tp|p=33290446|t=2020. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients.|pdf=|usr=022}}
| |
| − | {{tp|p=33267713|t=2020. COMPARE Analysis, a Bioinformatic Approach to Accelerate Drug Repurposing against Covid-19 and Other Emerging Epidemics.|pdf=|usr=022}}
| |
| − | {{tp|p=33295720|t=2020. COVID-19 hastalarinda serum vitamin D duzeyinin klinik seyir ve prognozla iliskisinin degerlendirilmesi.|pdf=|usr=022}}
| |
| − | {{tp|p=33277935|t=2020. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.|pdf=|usr=022}}
| |
